You are here

vutrisiran

5 FDA decisions to watch in the first quarter of 2025

BioPharma Dive

Mon, 01/6/25 - 06:54 pm

Vertex Pharmaceuticals

non-opioid pain treatments

transthyretin amyloid cardiomyopathy

diazoxide choline

Prader Willi syndrome

Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race

First Word Pharma

Tue, 11/26/24 - 11:04 am

Alnylam’s vutrisiran aces ATTR cardiomyopathy readout

Pharmaphorum

Mon, 06/24/24 - 10:52 am

Alnylam changes to heart drug trial spark doubts, sinking shares

BioPharma Dive

Thu, 02/15/24 - 07:13 pm

clinical trials

Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Pharmaphorum

Fri, 10/28/22 - 10:25 am

Stargardt disease

Inflation Reduction Act

Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'

Endpoints

Mon, 04/4/22 - 11:08 pm

The biggest launches of 2022: a reboot

EP Vantage

Mon, 02/14/22 - 10:48 am

Mirati Therapeutics

Bristol Myers Squibb

deucravacitinib

SFNP 2022 – Alnylam takes heart from its Onpattro follow-on

EP Vantage

Tue, 01/25/22 - 10:41 am

hereditary ATTR amyloidosis

Alnylam, awaiting key study data, builds case for its next rare disease drug

BioPharma Dive

Sat, 01/22/22 - 02:12 pm

7 drugs likely to hit $1B in annual revenue in the next 5 years

Beckers Hospital Review

Thu, 01/13/22 - 07:31 am

Mirati Therapeutics

AAN 2021 – Helios backs Alnylam’s sunny forecasts

EP Vantage

Wed, 04/21/21 - 10:28 am

hATTR amyloidosis

Biotech’s important clinical data readouts

EP Vantage

Fri, 03/26/21 - 10:35 am

spinal muscular atrophy

Primary Hyperoxaluria

Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing

Fierce Biotech

Thu, 01/7/21 - 11:33 am

clinical trials

ATTR amyloidosis

Alnylam's vutrisiran gets fast-track treatment at the FDA

Fierce Biotech

Tue, 04/14/20 - 09:44 am